Skip to main content

Medicina Personalizada para la mejora del tratamiento de la Leucemia Mieloide Aguda: combinación de terapias de precisión con un nanoconjugado de auristatina dirigido a las células madre leucémicas

PI24/00013

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2024
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU
Execution centre INSTITUT DE RECERCA SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Arnan, Montserrat
  • Pomares, Helena
  • Alonso, Ester
  • Tormo, Mar|||0000-0001-9622-1649
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Sampol, Antonia|||0000-0001-7465-6203
  • Coll, Rosa|||0000-0003-0560-1254
  • Salamero, Olga|||0000-0003-3237-0025
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Bargay, Joan|||0000-0002-6739-3916
  • Ortin, Xavier
  • Iranzo, Eva
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 fit adults ≤70 years intensively treated between 2012 and 2022 in the CETLAM group. Young adults ( ≤ 60 years) presented higher remission rates and improved survival than older adults above that age (CR 79% vs. 73%; p = 0.03 and 4-yr OS 53% vs. 33%; p < 0.001). Remission and survival outcomes varied among different genetic subsets. An especially adverse genetic group included complex, monosomal karyotype, TP53 alterations (deleted/mutated), and MECOMr. Transplant feasibility in this very adverse risk group was low, and OS and EFS at 4 years were 14% and 12%, in contrast to 70% and 57% in the favorable group and 38% and 32% in all other patients. We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

  • Garcia León, Annabel|||0000-0003-3007-9306
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Rueda, Ariana|||0000-0001-7588-9279
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sierra, Jorge|||0000-0002-7966-0356
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 cells while delivering the cytotoxic payload monomethyl auristatin E (MMAE). CXCR4 signaling pathway plays a critical role in LSC survival by preserving stem-like properties and activating protective mechanisms that promote treatment resistance. Moreover, CXCR4 is overexpressed in approximately 50 % of AML patients and is associated with poor prognosis and high relapse rates. We evaluated the therapeutic potential of T22-HSNBT-H6-MMAE using in vitro assays with AML cell lines and primary patient samples, as well as in vivo studies in a disseminated AML mouse model. Our results demonstrated that T22-HSNBT-H6-MMAE exerts a CXCR4-dependent cytotoxic effect through mitotic catastrophe and apoptosis induction in CXCR4 AML cell lines. In vivo evaluation in a disseminated CXCR4 AML mouse model showed potent antineoplastic activity, with complete suppression of leukemic dissemination and significantly prolonged survival, all without systemic toxicity. Notably, the nanoconjugate remained effective even in models with extensive bone marrow involvement and exhibited activity against diverse patient-derived CXCR4 AML blasts, while sparing healthy donor bone marrow and peripheral blood mononuclear cells (PBMCs) from significant toxicity. Collectively, these findings highlight T22-HSNBT-H6-MMAE as a promising therapeutic candidate for a broad range of AML patients, offering selective antineoplastic activity against CXCR4 leukemic cells.